# Paul Knoepfler

Type: Person

Source: GetYourBrief — https://getyourbrief.com/entity/paul-knoepfler
Canonical HTML page: https://getyourbrief.com/entity/paul-knoepfler

## Timeline

- **2026-07-24**: Advisory meeting concludes — The committee is expected to wrap up its evaluation and make recommendations that will guide the FDA's future compounding policy for peptides.
- **2026-07-23**: Two-day FDA advisory meeting begins — The Pharmacy Compounding Advisory Committee starts reviewing evidence for seven injectable peptides, including TB-500, BPC-157, and MOTs-C.

## Recent coverage (1 stories, network-wide)

### FDA Panel Reviews 7 Injectable Peptides Poised to Disrupt Telehealth and Longevity Care
2026-08-05 09:27:20 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 3

The FDA’s advisory committee meeting on seven unapproved injectable peptides could reshape the rapidly growing telehealth and wellness industry. A decision to allow compounding would legitimize a key offering for direct-to-consumer platforms, while a restrictive stance may intensify safety risks from the gray market. Healthcare providers and digital health innovators are watching closely.
Full story: https://gethealthbrief.com/story/fda-peptides-compounding-telehealth-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.